Content about Pharmacology

April 12, 2013

Acadia Pharmaceuticals can apply for approval of Parkinson's disease psychosis drug early

The Food and Drug Administration is granting an expedited application process to a company that has developed a treatment for a condition related to Parkinson's disease, meaning that it can cancel a planned late-stage clinical trial, the company said.

SAN DIEGO — The Food and Drug Administration is granting an expedited application process to a company that has developed a treatment for a condition related to Parkinson's disease, meaning that it can cancel a planned late-stage clinical trial, the company said.

April 12, 2013

Drug portfolio management teams devote more time, money to niche brands, study finds

Drug companies' pharmaceutical portfolio management teams spend most of their time and budgets supporting niche products, according to a new study.

RESEARCH TRIANGLE PARK, N.C. — Drug companies' pharmaceutical portfolio management teams spend most of their time and budgets supporting niche products, according to a new study.

April 12, 2013

FDA approves Lupin generic contraceptive

The Food and Drug Administration has approved a contraceptive therapy made by Lupin Pharmaceuticals, the Indian drug maker said Friday.

MUMBAI, India — The Food and Drug Administration has approved a contraceptive therapy made by Lupin Pharmaceuticals, the Indian drug maker said Friday.

Lupin announced the approval of Daysee (levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets) in the 0.15-mg/0.03-mg and 0.01-mg strengths.

The drug is a generic version of Teva's Seasonique. Various versions of the drug had sales of $161 million in 2012, according to IMS Health.

April 12, 2013

FDA investigation finds widespread problems at compounding pharmacies

An inspection of more than two-dozen compounding pharmacies by Food and Drug Administration officials has found widespread problems with sanitation and sterilization practices, FDA commissioner Margaret Hamburg wrote in a blog post on the agency's website Thursday.

SILVER SPRING, Md. — An inspection of more than two-dozen compounding pharmacies by Food and Drug Administration officials has found widespread problems with sanitation and sterilization practices, FDA commissioner Margaret Hamburg wrote in a blog post on the agency's website Thursday.

April 11, 2013

Chattem launches pair of topical anti-itch solutions under Allegra brand

Chattem announced the launch of Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream.

BRIDGEWATER, N.J. — Chattem on Thursday announced the launch of Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream.

"We identified an opportunity in the topical anti-itch category and leveraged our experience with Allegra Allergy to introduce a new product for common skin irritations that not only helps stop the itch but also provides a moisturizing benefit," stated John Stroud, EVP marketing, Chattem.

April 11, 2013

Congress leaders call out energy drink marketers to list caffeine content in investigative report

Three Democratic lawmakers on Wednesday released a report that found inconsistencies in the labeling and classification of energy drinks, extensive marketing to adolescents and young adults through social media and events, and high caffeine levels that exceed what is considered safe in soda by the Food and Drug Administration.

WASHINGTON — Three Democratic lawmakers on Wednesday released a report that found inconsistencies in the labeling and classification of energy drinks, extensive marketing to adolescents and young adults through social media and events, and high caffeine levels that exceed what is considered safe in soda by the Food and Drug Administration. The report was compiled using responses from 14 energy drink companies received by Rep. Ed Markey, D-Mass., and Sens. Richard Durbin, D-Ill., and Richard Blumenthal, D-Conn., from their investigation into the industry.

April 11, 2013

CVS Caremark releases annual insights report on drug spend

The increased availability of generics combined with CVS Caremark's generic dispensing rate of 77.4% helped reduce spending on traditional medications by 3.6% for the company's commercial clients, according to its newly released annual insights report.

WOONSOCKET, R.I. — The increased availability of generics combined with CVS Caremark's generic dispensing rate of 77.4% helped reduce spending on traditional medications by 3.6% for the company's commercial clients, according to its newly released annual insights report, which reviews drug trend and highlights key issues in pharmacy care.

CVS Caremark's GDR is the result of two elements. First, 2012 marked a high point in the flood of generic launches, with the estimated market value of brands that lost their patents in 2012 exceeding $35 billion.

April 11, 2013

QS/1 introduces 'first of its kind' Medicare Part B documentation system

QS/1 has released Medicare Part B compliance documentation, which it said would be the first of its type on the market to help pharmacies that want to serve Part B customers while remaining compliant, the company said.

SPARTANBURG, S.C. — QS/1 has released Medicare Part B compliance documentation, which it said would be the first of its type on the market to help pharmacies that want to serve Part B customers while remaining compliant, the company said.

QS/1 said its Medicare Part B Compliance Documentation software system was the first of its kind, allowing pharmacies using NRx or PrimeCare Pharmacy Management Systems to serve Medicare Part B customer needs while keeping necessary documents in the event of an audit.

April 11, 2013

Reports: Alberta government to give pharmacists allowance in preparation for generic pricing changes

The government of Canada's Alberta province will pay pharmacists $1 for each prescription filled as part of a one-year transition program for which it will spend $24 million, according to published reports.

NEW YORK — The government of Canada's Alberta province will pay pharmacists C$1 for each prescription filled as part of a one-year transition program for which it will spend $24 million, according to published reports.

April 11, 2013

Rite Aid posts $118.1 million profit for fiscal year 2013

Rite Aid's profits grew in the fourth quarter and fiscal year 2013 amid stronger front-end sales and prescription count, the retail pharmacy chain said.

CAMP HILL, Pa. — Rite Aid's profits grew in fourth quarter and fiscal year 2013 amid stronger front-end sales and prescription count, the retail pharmacy chain said Thursday.

April 11, 2013

Study finds wide disparities in antibiotic prescribing rates between South, Midwest

Research has indicated that about half of antibiotic prescriptions are unnecessary, raising concerns about the growth of bacteria resistant to them, but a new study by researchers at the Centers for Disease Control and Prevention also finds that prescriptions are highest in several states in the South and Midwest.

NEW YORK — Research has indicated that about half of antibiotic prescriptions are unnecessary, raising concerns about the growth of bacteria resistant to them, but a new study by researchers at the Centers for Disease Control and Prevention also finds that prescriptions are highest in several states in the South and Midwest.

The study, published Thursday in the New England Journal of Medicine, was based on a database maintained by IMS Health that includes a sample of more than 70% of U.S. prescriptions.

April 10, 2013

Cardinal Health Foundation helps combat Rx drug abuse with Generation Rx University

With the growing concern of the abuse of prescription stimulants like Adderall on college campuses, the Cardinal Health Foundation and the Ohio State University College of Pharmacy introduced Generation Rx University, the fourth in a series of interactive toolkits designed to help reduce the abuse of prescription drugs.

DUBLIN, Ohio — With the growing concern of the abuse of prescription stimulants like Adderall on college campuses, the Cardinal Health Foundation and the Ohio State University College of Pharmacy on Wednesday introduced Generation Rx University, the fourth in a series of interactive toolkits designed to help reduce the abuse of prescription drugs.

April 9, 2013

Pharmaceutical balance tipping to specialty side

The new world of targeted, specialized medicines — many of them bioengineered and many of them aimed at smaller and smaller segments of the population — isn’t just on its way. It’s here. And it’s going to radically change the practice of pharmacy.

Here’s an eye-opener: Specialty drugs will likely account for 50% of all drug costs by 2018, up from 28.7% of total prescription drug costs in 2012.

April 8, 2013

CRN issues marketing guidelines for caffeine-containing dietary supplement products

The Council for Responsible Nutrition issued recommended guidelines for caffeine-containing dietary supplement products, expanding its self-regulatory initiatives that encourage best practices within the supplement industry.

WASHINGTON — The Council for Responsible Nutrition last week issued recommended guidelines for caffeine-containing dietary supplement products, expanding its self-regulatory initiatives that encourage best practices within the supplement industry.

April 8, 2013

Patients taking AstraZeneca RA drug show partial improvement

An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

NEW YORK — An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

AstraZeneca announced initial results of the phase-3 "OSKIRA-1" trial of fostamatinib, which it calls the first oral spleen tyrosine kinase inhibitor in development for RA.

April 8, 2013

Teva introduces generic painkiller

Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.

NORTH WALES, Pa. — Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.

Teva announced the introduction of oxymorphone hydrochloride tablets.

The drug is a generic version of Endo Pharmaceuticals' Opana and will be available in the 5 mg and 10 mg strengths in bottles of 100 tablets.

April 5, 2013

Actavis to market, distribute authorized generic version of Valeant drug; Valeant to co-promote Actavis drug

Actavis will market and distribute an authorized generic version of a genital herpes ointment made by Valeant Pharmaceuticals International, the companies said Friday.

PARSIPPANY, N.J. — Actavis will market and distribute an authorized generic version of a genital herpes ointment made by Valeant Pharmaceuticals International, the companies said Friday.

The agreement centers around Zovirax, known generically as acyclovir, in the 5% strength. The Food and Drug Administration approved the generic version, made by Mylan, on Wednesday. Financial terms of the deal were not disclosed.

April 5, 2013

District Court orders FDA to lift prescription restriction of Plan B One-Step for underage women

The Food and Drug Administration has 30 days to approve over-the-counter availability of the emergency contraceptive Plan B One-Step to women of all ages, according to a decision issued by Judge Edward Korman of the U.S. District Court, Eastern District of New York.

NEW YORK — The Food and Drug Administration has 30 days to approve over-the-counter availability of the emergency contraceptive Plan B One-Step to women of all ages, according to a decision issued Friday by Judge Edward Korman of the United States District Court, Eastern District of New York. In a second decision, Korman declined to intervene on Teva Pharma's behalf in extending patent exclusivity for Plan B One-Step.

April 5, 2013

NIH funds drug-herb interaction research at University of Illinois at Chicago College of Pharmacy

The University of Illinois at Chicago College of Pharmacy on Wednesday announced that it is the recipient of a five-year, $2.1 million grant to train graduate and postdoctoral students in natural product drugs and dietary supplements.

CHICAGO — The University of Illinois at Chicago College of Pharmacy on Wednesday announced that it is the recipient of a five-year, $2.1 million grant to train graduate and postdoctoral students in natural product drugs and dietary supplements. The grant is funded by the National Center for Complementary and Alternative Medicine, one of the National Institutes of Health.

April 4, 2013

Allergy Relief 2013

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

April 4, 2013

Covis buys rights to five drugs from Sanofi

Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said.

ZUG, Switzerland — Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said Thursday.

April 4, 2013

FDA grants tentative approval to Aurobindo HIV drug

The Food and Drug Administration has given preliminary approval to a drug made by Aurobindo Pharma for treating HIV infection, the drug maker said.

HYDERABAD, India — The Food and Drug Administration has given preliminary approval to a drug made by Aurobindo Pharma for treating HIV infection in developing countries, the drug maker said.

Aurobindo announced that it had received tentative approval for efavirenz/emtricitabine/tenofovir disoproxil fumarate combination tablets in the 600-mg/200 mg/300-mg strength. The drug is a generic version of Gilead Sciences' Atripla.

April 4, 2013

Florida Senate committee passes biosimilar bill

A committee of Florida's state Senate has passed a bill that could limit the use of biosimilars in the state.

WASHINGTON — A committee of Florida's state Senate has passed a bill that could limit the use of biosimilars in the state.

The Florida Senate Committee on Health Policy passed S.B. 732, sending it to the full state senate. The legislation would require pharmacists to inform doctors when a follow-on biologic was substituted for a brand-name biotech drug. The bill is similar to one signed into law last month by Virginia Gov. Bob McDonnell.

April 4, 2013

Reports: Novartis launches new ad campaign aimed at young adults

Novartis is promoting the multiple sclerosis drug Gilenya to young people with a new ad campaign in several national magazine's and websites, according to published reports.

NEW YORK — Novartis is promoting the multiple sclerosis drug Gilenya to young people with a new ad campaign in several national magazine's and websites, according to published reports.

The New York Times reported that the Swiss drug maker had placed ads for its "Hey MS, Take This!" campaign in People, Shape and Self, as well as the website of women's magazines, in addition to online videos. The generic name of Gilenya is fingolimod.

April 4, 2013

Rite Aid front-end comps up 3.8% amid shift in timing of Easter

Same-store sales at Rite Aid decreased 2% in March, including a 3.8% increase in same-store sales on the front end and a 4.5% decrease in pharmacy sales due in part to new introductions of generic drugs, the retail pharmacy chain said.

CAMP HILL, Pa. — Same-store sales at Rite Aid decreased 2% in March, including a 3.8% increase in same-store sales on the front end and a 4.5% decrease in pharmacy sales due in part to new introductions of generic drugs, the retail pharmacy chain said Thursday.

The 4,621-store chain reported total sales for the month of $1.939 billion, a 2.5% decrease compared with $1.989 billion in March 2012, while same-store prescription count increased 0.3%.